Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
Seefeld, M.A., Miller, W.H., Newlander, K.A., Burgess, W.J., Payne, D.J., Rittenhouse, S.F., Moore, T.D., DeWolf, W.E., Keller, P.M., Qiu, X., Janson, C.A., Vaidya, K., Fosberry, A.P., Smyth, M.G., Jaworski, D.D., Slater-Radosti, C., Huffman, W.F.(2001) Bioorg Med Chem Lett 11: 2241-2244
- PubMed: 11527706 
- DOI: https://doi.org/10.1016/s0960-894x(01)00405-x
- Primary Citation of Related Structures:  
1I30 - PubMed Abstract: 
An SAR study of a screening lead has led to the identification of 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as inhibitors of Staphylococcus aureus enoyl acyl carrier protein reductase (FabI).
Organizational Affiliation: 
GlaxoSmithKline Pharmaceuticals, Antimicrobial and Host Defense Division, 1250 S. Collegeville Road, Collegeville, PA 19426, USA. mark_a_seefeld@sbphrd.com